What is Glaukos Corp?
Headquartered in Aliso Viejo, California, Glaukos Corporation is a specialized medical technology and pharmaceutical firm dedicated to the development of novel therapies for glaucoma, corneal disorders, and retinal diseases. The company is widely recognized for its pioneering work in micro-invasive glaucoma surgery, specifically through its iStent and iStent inject W platforms, which facilitate aqueous humor outflow. By integrating procedural pharmaceutical therapies like iDose TR into its portfolio, Glaukos addresses critical gaps in the treatment of intraocular pressure, positioning itself as a leader in ophthalmic innovation. The company utilizes a sophisticated direct sales organization and international distribution network to ensure its therapeutic solutions reach patients globally.
How much funding has Glaukos Corp raised?
Glaukos Corp has raised a total of $187.3M across 4 funding rounds:
Series A
$10M
Series D
$35M
Series F
$30M
Stock Offering
$112.3M
Series A (2002): $10M with participation from Domain Associates, Versant Ventures, and Frazier Healthcare Partners
Series D (2008): $35M led by InterWest Partners, Domain Associates, Montreux Equity Partners, Versant Ventures, OrbiMed, Fjord Ventures, and Frazier Healthcare Partners
Series F (2013): $30M supported by Versant Ventures, InterWest Partners, Domain Associates, Meritech, Montreux Equity Partners, OrbiMed, and Frazier Healthcare Partners
Stock Issuance/Offering (2015): $112.3M, investors not publicly disclosed
Key Investors in Glaukos Corp
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a focus on biopharmaceutical and diagnostic companies.
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies, leveraging extensive scientific and venture capital expertise.
Frazier Healthcare Partners
Frazier Healthcare Partners is a prominent investment firm focused on the biopharmaceutical sector, supporting the development and commercialization of new medical treatments.
What's next for Glaukos Corp?
With the support of its strategic investment partners, Glaukos is well-positioned to accelerate the commercialization of its advanced pipeline, including the iStent Infinite and iDose TR platforms. The company's focus remains on expanding its market share in the United States and abroad while continuing to refine its clinical approach to glaucoma management. Future growth will likely be driven by the continued adoption of its micro-bypass stent technology and the successful integration of new pharmaceutical assets into its existing clinical framework. As the firm matures, it is expected to leverage its established infrastructure to explore further therapeutic indications, maintaining its commitment to improving patient outcomes through high-precision medical interventions.
See full Glaukos Corp company page
